Your Article Summary
See Latest ArticlesPhase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Journal of Neuro-Oncology, 07/02/09
Wen PY et al. - Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma. The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted.
Related Articles
A meningioma of the scalp that might have developed from a rudimentary meningocele
Clinical and Experimental Dermatology, 10/16/09
Relevance Score: 90%
Jugular fossa meningioma: Presentation and treatment options
ENT Journal, 10/21/09
Relevance Score: 89%
Diagnosis and Treatment of the Primary Malignant Meningioma in Mediastinum: A Case Report
Southern Medical Journal, 11/10/09
Relevance Score: 88%
Radiation-induced meningiomas: A shadow in the success story of childhood leukemia
Neuro-Oncology, 10/06/09
Relevance Score: 88%
Does protein expression predict recurrence of benign World Health Organization grade I meningioma
Human Pathology, 10/08/09
Relevance Score: 87%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Genomic Landscape of Meningiomas
Brain Pathology, 12/15/09
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
Journal of Neuro-Oncology, 12/15/09
Control of brain metastases using frameless image-guided radiosurgery
Neurosurgical Focus, 12/15/09